Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Recher

Showing results (111-120 of 136) with videos related to

Pageof 14
Sort By:
Blood|December 19, 2009
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceLionel Adès, Agnes Guerci, Emmanuel Raffoux, et al.
Haematologica|June 1, 2023
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinibRuben Mesa, Srdan Verstovsek, Uwe Platzbecker, et al.
Blood|January 17, 2013
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaEric Jourdan, Nicolas Boissel, Sylvie Chevret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2017
Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS StudyArnaud Pigneux, Marie C Béné, Philippe Guardiola, et al.
Blood Advances|February 11, 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohortEdmond Chiche, Ramy Rahmé, Sarah Bertoli, et al.
Blood|October 14, 2010
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineRaphael Itzykson, Sylvain Thépot, Bruno Quesnel, et al.
Blood Cancer Journal|April 21, 2022
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemiaKeith W Pratz, Panayiotis Panayiotidis, Christian Recher, et al.
Blood|April 21, 2021
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA studyMatthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2021
Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)Thomas Cluzeau, Marie Sebert, Ramy Rahmé, et al.
Nature Communications|May 26, 2021
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patientsFlorent Malard, Anne Vekhoff, Simona Lapusan, et al.
Pageof 14

Showing results (111-120 of 136) with videos related to

Sort By:
Pageof 14
Blood|December 19, 2009
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceLionel Adès, Agnes Guerci, Emmanuel Raffoux, et al.
Haematologica|June 1, 2023
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinibRuben Mesa, Srdan Verstovsek, Uwe Platzbecker, et al.
Blood|January 17, 2013
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaEric Jourdan, Nicolas Boissel, Sylvie Chevret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2017
Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS StudyArnaud Pigneux, Marie C Béné, Philippe Guardiola, et al.
Blood Advances|February 11, 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohortEdmond Chiche, Ramy Rahmé, Sarah Bertoli, et al.
Blood|October 14, 2010
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineRaphael Itzykson, Sylvain Thépot, Bruno Quesnel, et al.
Blood Cancer Journal|April 21, 2022
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemiaKeith W Pratz, Panayiotis Panayiotidis, Christian Recher, et al.
Blood|April 21, 2021
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA studyMatthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2021
Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)Thomas Cluzeau, Marie Sebert, Ramy Rahmé, et al.
Nature Communications|May 26, 2021
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patientsFlorent Malard, Anne Vekhoff, Simona Lapusan, et al.
Pageof 14